Fax (507) 284-1803
A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma †‡§¶
A North Central Cancer Treatment Group study, N0775
Article first published online: 22 AUG 2012
Copyright © 2012 American Cancer Society
Volume 119, Issue 3, pages 586–592, 1 February 2013
How to Cite
Kottschade, L. A., Suman, V. J., Perez, D. G., McWilliams, R. R., Kaur, J. S., Amatruda, T. T., Geoffroy, F. J., Gross, H. M., Cohen, P. A., Jaslowski, A. J., Kosel, M. L. and Markovic, S. N. (2013), A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma . Cancer, 119: 586–592. doi: 10.1002/cncr.27760
The content of this article is solely the responsibility of the authors and does not necessarily represent the views of the National Cancer Institute or the National Institutes of Health.
This study was presented at the American Society for Clinical Oncology 2011 Annual Meeting, June 3 to 7, Chicago, Illinois, as a poster discussion.
Additional participating institutions include: Geisinger Clinic and Medical Center CCOP, Danville, PA (Albert M. Bernath, Jr, MD); Columbus CCOP, Columbus, OH (J. Philip Kuebler, MD, PhD); Grand Rapids Clinical Oncology Program, Grand Rapids, MI (Martin J. Bury, MD); Michigan Cancer Research Consortium, Ann Arbor, MI (Philip J. Stella, MD); Iowa Oncology Research Association CCOP, Des Moines, IA (Robert J. Behrens, MD); Duluth CCOP, Duluth, MN (Daniel A. Nikcevich, MD); Meritcare Hospital CCOP, Fargo, ND (Preston D. Steen, MD); Lehigh Valley Hospital, Allentown, PA (Suresh Nair, MD); Cedar Rapids Oncology Project CCOP, Cedar Rapids, IA (Martin Wiesenfeld, MD); Colorado Cancer Research Program, Denver, CO (Eduardo R. Pajon, Jr, MD); Missouri Valley Cancer Consortium Omaha, NE (Gamini S. Soori, MD); Toledo Community Hospital Oncology Program CCOP, Toledo, OH (Rex B. Mowat, MD); Wichita Community Clinical Oncology Program, Wichita, KS (Shaker R. Dakhil, MD); Northern Indiana Cancer Research Consortium CCOP, South Bend, IN (Robin T. Zon, MD); Rapid City Regional Oncology Group, Rapid City, SD (Richard C. Tenglin, MD); Sioux Community Cancer Consortium, Sioux Falls, SD (Miroslaw Mazurczak, MD); Montana Cancer Consortium, Billings, MT (Benjamin T. Marchello, MD); Cancer Research for the Ozarks, Springfield, MO (Robert L Carolla, MD); CentraCare Clinic, St. Cloud, MN (Donald J. Jurgens, MD); and Virgina Mason CCOP, Seattle, WA (Jacqueline Vuky, MD).
See editorial on pages 477–80, this issue.
- Issue published online: 22 JAN 2013
- Article first published online: 22 AUG 2012
- Manuscript Accepted: 29 MAR 2012
- Manuscript Revised: 5 MAR 2012
- Manuscript Received: 21 DEC 2011
- metastatic melanoma;
- vascular endothelial growth factor inhibition;
- combination therapy;
- unresectable metastatic melanoma
Increasing evidence shows chemotherapy in combination with vascular endothelial growth factor (VEGF) inhibition is a clinically active therapy for patients with metastatic melanoma (MM).
A phase 2 trial was conducted in chemotherapy-naive patients with unresectable stage IV MM who were randomized to temozolomide (200 mg/m2 on days 1 through 5) and bevacizumab (10 mg/kg intravenously on days 1 and 15) every 28 days (Regimen TB) or nab-paclitaxel (100 mg/m2, or 80 mg/m2 post-addendum 5 secondary to toxicity, on days 1, 8, and 15), bevacizumab (10 mg/kg on days 1 and 15), and carboplatin (area under the curve [AUC] 6 on day 1, or AUC 5 post-addendum 5) every 28 days (Regimen ABC). Accrual goal was 41 patients per regimen. The primary aim of this study was to estimate progression-free survival rate at 6 months (PFS6) in each regimen. A regimen would be considered promising if its PFS6 rate was > 60%.
Ninety-three eligible patients (42 TB and 51 ABC) were enrolled. The majority of patients had M1c disease (20 TB and 26 ABC). The median PFS and overall survival times with ABC were 6.7 months and 13.9 months, respectively. Median PFS time and median overall survival with TB were 3.8 months and 12.3 months, respectively. The most common severe toxicities (≥ grade 3) in both regimens were cytopenias, fatigue, and thrombosis. Among the first 41 patients enrolled onto each regimen, PFS6 rate was 32.8% (95% confidence interval: 21.1%-51.2%) for TB and 56.1% (90% confidence interval: 44.7%-70.4%) for ABC.
The addition of bevacizumab to nab-paclitaxel and carboplatin shows promising activity despite tolerability issues. Cancer 2013. © 2012 American Cancer Society.